2021-11-15T18:58:01-06:00 2020-12-31 814234542 BPM LLP 4200 BOHANNON DRIVE SUITE 250 MENLO PARK CA 940251021 990 2020-01-01 204284925 QUANTUM LEAP HEALTHCARE COLLABORATIVE QUAN 8558660505 3450 CALIFORNIA STREET 2ND FLOOR SAN FRANCISCO CA 941181837 JAMES PALAZZOLO CEO 8558660505 2021-11-15 1 JAMES PALAZZOLO 999009999 CAROLYN R AMSTER P00189994 6508556800 2021-11-15 2 AAL1 IAL1 2020 2022-09-23 18:48:47Z JAMES PALAZZOLO 3450 CALIFORNIA STREET 2ND FLOOR SAN FRANCISCO CA 941181837 50487169 0 X WWW.QUANTUMLEAPHEALTH.ORG X 2005 CA THE MISSION OF QUANTUM LEAP HEALTHCARE COLLABORATIVE IS TO PROVIDE MANAGEMENT AND FINANCIAL SUPPORT TO HEALTHCARE RESEARCH ORGANIZATIONS, PARTICULARLY INVOLVING BREAST CANCER AND COVID-19 RESEARCH AND TREATMENT. 13 12 40 12 0 0 1876103 12701393 13088922 28181045 119258 86104 4890 -1884 15089173 40966658 297497 35000 0 0 2619028 4039299 0 0 242364 11722540 19481659 14639065 23555958 450108 17410700 16681889 46710842 15939504 28501320 742385 18209522 X THE MISSION OF QUANTUM LEAP HEALTHCARE COLLABORATIVE IS TO PROVIDE MANAGEMENT AND FINANCIAL SUPPORT TO HEALTHCARE RESEARCH ORGANIZATIONS, PARTICULARLY INVOLVING BREAST CANCER RESEARCH AND TREATMENT. 0 0 17492317 35000 27071045 I-SPY TRIALS: QUANTUM LEAP SPONSORS THE I-SPY TRIALS (INVESTIGATION OF SERIAL STUDIES TO PREDICT YOUR THERAPEUTIC RESPONSE WITH IMAGING AND MOLECULAR ANALYSIS). I-SPY HAS BEEN RE-ENGINEERING THE APPROACH TO CLINICAL TRIALS, WITH A GOAL OF GETTING THE RIGHT DRUG TO THE RIGHT PATIENT AT THE TIME WHEN THEY WILL BENEFIT MOST, AND TO ACHIEVE THIS FASTER THAN POSSIBLE IN PREVIOUS TRIAL MODELS. ADDITIONALLY, I-SPY AIMS TO SIGNIFICANTLY REDUCE THE OVERALL COST, TIME, AND NUMBER OF PATIENTS REQUIRED TO BRING NEW DRUGS TO MARKET. THE I-SPY TRIAL PROGRAM INTEGRATES AND LINKS PHASE I (I-SPY PHASE 1), PHASE II (I-SPY 2), AND FUTURE PHASES TO BUILD A PIPELINE OF NOVEL AGENTS AND ACCELERATE THE PROCESS OF IDENTIFYING THE SUBSET OF HIGH-RISK BREAST CANCER PATIENTS THAT WILL BENEFIT FROM THESE NEW AGENTS, AND GET THESE DRUG INTO THE CLINIC IN A TIMELY MANNER. 782032 BREAST CANCER TRAILS (BCT) - LAUNCHED IN 2008, FOLLOWING A SUCCESSFUL UCSF-NCI SPONSORED RESEARCH PILOT, ITS MISSION IS TO MAKE PATIENT CONSIDERATION OF TRIALS THE NORM VS. THE EXCEPTION. WE BELIEVE THAT ALL PATIENTS SHOULD HAVE ACCESS TO THE LATEST MEDICAL KNOWLEDGE ABOUT BREAST CANCER TREATMENT AS WELL AS THE OPPORTUNITY TO ADVANCE BREAST CANCER RESEARCH. BCT LISTS OVER 600 STUDIES FOR PEOPLE WITH NEWLY DIAGNOSED BREAST CANCER, METASTATIC DISEASE, OR POST-TREATMENT SURVIVORS. IT INCLUDES INNOVATIVE TRIALS OF TARGETED AND IMMUNOTHERAPIES AS WELL AS OBSERVATIONAL STUDIES LOOKING AT QUALITY OF LIFE, GENETIC MUTATIONS, AND BREAST CANCER SURVIVORSHIP, ACCOMPANIED BY EASY-TO-READ TRIAL SUMMARIES. 449963 60000 COLLABORATION WITH THE ATHENA BREAST HEALTH NETWORK - THE ATHENA BREAST HEALTH NETWORK ("ATHENA") IS A COLLABORATION OF THE FIVE UNIVERSITY OF CALIFORNIA MEDICAL CENTERS AND SANFORD HEALTH TO DRIVE INNOVATION IN BREAST CANCER PREVENTION, SCREENING AND TREATMENT. A LARGE-SCALE DEMONSTRATION PROJECT, ATHENA INTEGRATES CLINICAL CARE AND RESEARCH TO DRIVE INNOVATION IN PREVENTION, SCREENING, TREATMENT AND MANAGEMENT OF BREAST CANCER. THIS PROJECT WILL IMPROVE SURVIVAL AND REDUCE SUFFERING FROM BREAST CANCER BY ACCELERATING THE TIME BETWEEN RESEARCH DISCOVERIES AND INNOVATIVE PATIENT TREATMENTS. MAJOR INITIATIVES INCLUDE RISK ASSESSMENT AND EVALUATION, RADIOLOGY HARMONIZATION, PATHOLOGY HARMONIZATION, AND IMPROVING SURVIVORSHIP CARE. 2848335 1050000 2848335 1050000 21572647 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 1 45 0 1 40 0 0 0 0 0 0 0 0 0 0 0 0 0 X 13 12 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA X X X THE ORGANIZATION 8558660505 3450 CALIFORNIA STREET 2ND FLOOR SAN FRANCISCO CA 941181837 LAURA ESSERMAN DIRECTOR, COFOUNDER 20.00 X X 0 0 0 JEFFREY PFEFFER DIRECTOR, COFOUNDER 0.50 X X 0 0 0 DAVE MANDELKERN CHAIRMAN 12.00 X X 121505 0 0 ANNA BARKER DIRECTOR 0.50 X 0 0 0 LUCAS DEBREED DIRECTOR 0.50 X 0 0 0 SUSAN FOLEY TREASURER 0.50 X X 0 0 0 MICHELE MARKUS DIRECTOR 0.50 X 0 0 0 ROBERT PATTERSON DIRECTOR 0.50 X 0 0 0 ROBYN LAWRIE RUTLEDGE DIRECTOR 0.50 X 0 0 0 GREGORY C SIMON DIRECTOR 0.50 X 0 0 0 MARK SIMON DIRECTOR 0.50 X 0 0 0 N MARCUS THYGESON DIRECTOR 0.50 X 0 0 0 LAMBERT VAN DER WALDE DIRECTOR 0.50 X 0 0 0 JAMES PALAZZOLO CEO 40.00 X 295000 0 0 PAUL HENDERSON SENIOR DIRECTOR OF COLLABORATIONS 40.00 X 163479 0 6072 KARYN DIGIORGIO COO 40.00 X 217015 0 6569 TRACEY L HEATHER DIRECTOR OF DEVELOPMENT 40.00 X 165140 0 6720 MICHAEL RESENDEZ SENIOR SOFTWARE ENGINEER 40.00 X 147459 0 4423 KATHRYN J WATSON-FEINER DIRECTOR OF FINANCE 40.00 X 215007 0 7600 1324605 0 31384 12 0 1 0 OWL BROOK ASSOCIATES LLC PO BOX 5218 HANOVER NH 03755 CLINICAL DATA WORKFLOW, DESIGN, & TESTIN 307063 SURESH GADAMSETTY 1501 DECOTO ROAD APT 118 UNION CITY CA 94587 SOFTWARE DEVELOPMENT AND TECHNICAL ASSIS 201915 STEFFANIE GOODMAN 2030 FELL STREET 2 SAN FRANCISCO CA 94117 CONSULTING SERVICE 170800 BPM LLP ONE CALIFORNIA STREET SUITE 2500 SAN FRANCISCO CA 94111 TAX AND AUDIT SERVICES 153530 DAVID MANDELKERN PO BOX 19564 STANFORD CA 94309 MANAGEMENT CONSULTING AND ASSISTANCE TO 121505 5 186991 9613905 2900497 186991 12701393 CLINICAL TRIAL CONTRACTS 541511 28121045 28121045 CONSULTING AND RESEARCH CONTRACTS 541511 60000 60000 28181045 56784 56784 9453000 3302 9422184 4798 30816 -1496 29320 29320 91645 186991 93529 -1884 -1884 40966658 28181045 0 84220 X 35000 35000 416504 298846 101108 16550 2894164 1949259 776123 168782 65043 44167 17235 3641 453947 308252 120283 25412 209641 142356 55549 11736 80507 65282 15201 24 159273 129152 30073 48 2693428 2184061 508564 803 2137193 2089425 34251 13517 163478 116771 46707 14007 12537 1470 2245 2245 22887 14930 7957 52853 46509 6344 RESEARCH SITES 7384149 7384149 PROGRAM MANAGEMENT 6690887 6690887 EVENTS 45527 45259 268 OTHER PROGRAM EXPENSES 31615 13517 17644 454 3610 2288 193 1129 23555958 21572647 1740947 242364 255778 4496261 3589960 18411525 298498 9708493 3197897 12302273 93609 271841 228131 116506 42995 29568 73511 8941267 1394394 97080 2645 16681889 46710842 10661346 17442360 5278158 11058960 15939504 28501320 X -1117638 15697161 1860023 2512361 742385 18209522 16681889 46710842 17410700 56438 0 X X 0 1 X 1 0 X 1285937 3033157 1203352 1876103 12652517 20051066 1285937 3033157 1203352 1876103 12652517 20051066 3352062 16699004 121682 87600 209282 20260348 71078172 0.82420 0.48830 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 116506 42995 73511 73511 X 41024980 56439 1884 58323 40966657 0 40966657 23557842 1884 1884 23555958 0 23555958 PART X, LINE 2: QUANTUM LEAP IS EXEMPT FROM FEDERAL AND STATE INCOME TAXES UNDER THE PROVISIONS OF SECTION 501(C)(3) AND SECTION 170(B)(1)(A)(VI) OF THE INTERNAL REVENUE CODE AND CORRESPONDING PROVISIONS OF THE CALIFORNIA REVENUE AND TAXATION CODE. ACCORDINGLY, NO PROVISION FOR INCOME TAXES HAS BEEN MADE IN THE ACCOMPANYING FINANCIAL STATEMENTS. QUANTUM LEAP MAY BE SUBJECT TO UNRELATED BUSINESS INCOME TAX. PART XI, LINE 2D - OTHER ADJUSTMENTS: FUNDRAISING DIRECT EXPENSES 1,884. PART XII, LINE 2D - OTHER ADJUSTMENTS: FUNDRAISING DIRECT EXPENSES 1,884. X 0 CA ONLINE AUCTION 278636 186991 91645 93529 278636 186991 91645 93529 93529 -1884 0 UCSF FOUNDATION 220 MONTGOMERY ST 5TH FLOOR SAN FRANCISCO CA 94104 942829914 501(C)(3) 35000 WHOLE GENOME GENOTYPING IN I-SPY 2 PATIENT POPULATIONS 1 0 X 0 0 0 0 0 0 0 0 0 JAMES PALAZZOLO CEO 295000 0 0 0 0 0 0 0 0 0 295000 0 0 0 KARYN DIGIORGIO COO 217015 0 0 0 0 0 6569 0 0 0 223584 0 0 0 KATHRYN J WATSON-FEINER DIRECTOR OF FINANCE 215007 0 0 0 0 0 7600 0 0 0 222607 0 0 0 TRACEY L HEATHER DIRECTOR OF DEVELOPMENT 165140 0 0 0 0 0 6720 0 0 0 171860 0 0 0 PAUL HENDERSON SENIOR DIRECTOR OF COLLABORATIONS 163479 0 0 0 0 0 6072 0 0 0 169551 0 0 0 MICHAEL RESENDEZ SENIOR SOFTWARE ENGINEER 147459 0 0 0 0 0 4423 0 0 0 151882 0 0 0 DAVE MANDELKERN CHAIRMAN 121505 0 0 0 0 0 0 0 0 0 121505 0 0 0 X 45 185254 FAIR MARKET VALUE X WINE 5 1737 FAIR MARKET VALUE 0 0 0 PART I, COLUMN (B): THE NUMBER PRESENTED ABOVE REPRESENTS THE NUMBER OF SEPARATE PIECES OF ARTWORK AND THE NUMBER OF CASES OF WINE CONTRIBUTED TO THE ORGANIZATION FOR ITS ONLINE AUCTION FUNDRAISING EVENT. FORM 990, PART VI, SECTION B, LINE 11B FORM 990 IS PREPARED BY AN INDEPENDENT CPA FIRM IN CONJUNCTION WITH THE ORGANIZATION'S DIRECTOR OF FINANCE. A DRAFT OF FORM 990 IS REVIEWED BY THE DIRECTOR OF FINANCE, AND CORRECTIONS/MODIFICATIONS ARE MADE BY THE OUTSIDE CPA. THE REVISED DRAFT IS THEN REVIEWED BY THE DIRECTOR OF FINANCE. ANY CONCERNS ARE RAISED WITH THE CPA FIRM AND A CONSENSUS IS ACHIEVED. BOARD MEMBERS ARE SENT A COPY OF THE TAX RETURN PRIOR TO FILING FOR THEIR REVIEW. THE RETURN IS THEN FINALIZED AND ELECTRONICALLY FILED WITH THE TAXING AUTHORITIES. FORM 990, PART VI, SECTION B, LINE 12C THE CONFLICT OF INTEREST POLICY IS PRESENTED AND REVIEWED ANNUALLY. EACH BOARD MEMBER IS REQUIRED TO ACKNOWLEDGE IN WRITING THAT NO CONFLICT EXISTS. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION OF THE PRESIDENT OF THE ORGANIZATION WAS DETERMINED AND APPROVED BY VOTE OF THE BOARD OF DIRECTORS. PERSONNEL OF UCSF REVIEWED JOB REQUIREMENTS AGAINST TECHNICAL ABILITIES OF SUBCONTRACTORS AND DETERMINED WHETHER OR NOT THEY MATCHED. ALL SUBCONTRACTORS WERE ENGAGED AT BELOW-MARKET RATES. FORM 990, PART VI, SECTION C, LINE 19 ALL GOVERNING DOCUMENTS, AUDITED FINANCIAL STATEMENTS AND FORM 990, RETURN OF ORGANIZATION EXEMPT FROM INCOME TAX, ARE PROVIDED UPON WRITTEN REQUEST OR THROUGH THE QUANTUM LEAP HEALTHCARE COLLABORATIVE WEBSITE, AS WELL AS TO ANYONE WHO REQUESTS THEM IN WRITING. THEY ARE ALSO AVAILABLE FOR INSPECTION AT THE QLHC OFFICE DURING NORMAL BUSINESS HOURS. FORM 990, PART IX, LINE 11G OTHER PROFESSIONAL FEES: PROGRAM SERVICE EXPENSES 2,184,061. MANAGEMENT AND GENERAL EXPENSES 508,564. FUNDRAISING EXPENSES 803. TOTAL EXPENSES 2,693,428. FORM 990, PART XII, LINE 2C: THE FINANCIALS WERE PREVIOUSLY PREPARED ON A CONSOLIDATED BASIS. THE RELATED ORGANIZATION WAS DISSOLVED IN THE PRIOR YEAR. THE FINANCIALS ARE NOW PREPARED ON A SEPARATE BASIS.